Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic and Hypolipidemic Agents (Proceedings of the Ninth Annual Symposium on New Drugs and Devices, October 27 & 28, 1988). Edited by Joel Morganroth and E. Neil Moore Kluwer Academic Publishers, Boston (1989) 375 pages, illustrated, $80.00 ISBN: 0‐79230‐294‐X [PDF]
Richelle Charles
openalex +1 more source
Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coactivator-Dependent Receptor Ligand Assay [PDF]
Grigorios Krey +6 more
openalex +1 more source
Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents. [PDF]
Bjørndal B +4 more
europepmc +1 more source
Novel Hypolipidemic Agents: Focus on PCSK9 Inhibitors
Antonis S. Manolis +2 more
openalex +2 more sources
Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study. [PDF]
Cortés-Salgado A +19 more
europepmc +1 more source
Beneficial Effects of Ginger as Hypoglyemic, Hypolipidemic, Anti-obesity, Anti-oxidant, and Anti-inflammatory Agent in Adult Female albino Rats [PDF]
Mona El-Karn +2 more
openalex +1 more source
Multi-Targeting Valproic Acid Conjugates as Potent Agents Against Inflammation and Hyperlipidemia. [PDF]
Theodosis-Nobelos P, Rekka EA.
europepmc +1 more source
Unlocking the Therapeutic Potential of <i>Trigonella foenum-graecum</i> and <i>Trigonella corniculata</i> Against High-Fat-Diet-Induced Hyperlipidemia: Antioxidant and Histopathological Evidence. [PDF]
Shamim R +10 more
europepmc +1 more source

